MXC.AX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 bal. 2024 @ 08:10):

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines...

Stats
Šios dienos apimtis	47 232.00
Vidutinė apimtis	23 177.00
Rinkos kapitalizacija	18.42M
EPS	$0 ( 2024-02-25 )
Kita pelno data	( $0 ) 2024-07-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.0240 (5.78%)

Tūris Koreliacija

Ilgas: -0.04 (neutral)

Trumpas: 0.36 (neutral)

Signal:(47.63) Neutral

MGC Pharmaceuticals Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

MGC Pharmaceuticals Ltd Koreliacija - Valiuta/Žaliavos

0.30
( neutral )

-0.03
( neutral )

0.00
( neutral )

0.57
( weak )

-0.48
( neutral )

-0.66
( moderate negative )

MGC Pharmaceuticals Ltd Finansinės ataskaitos

Annual	2023
Pajamos:	$3.39M
Bruto pelnas:	$698 740 (20.63 %)
EPS:	$-7.07

FY	2023
Pajamos:	$3.39M
Bruto pelnas:	$698 740 (20.63 %)
EPS:	$-7.07

FY	2022
Pajamos:	$4.73M
Bruto pelnas:	$1.56M (33.01 %)
EPS:	$-7.93

FY	2021
Pajamos:	$2.96M
Bruto pelnas:	$1.31M (44.23 %)
EPS:	$-0.0115

Financial Reports:

No articles found.

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.